MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.70073

Медицинская библиотека · European journal of heart failure · 2025

Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.

Venneri Lucia, Aimo Alberto, Porcari Aldostefano, Sezer Irem, Ioannou Adam, Sheikh Awais, Mansell Josephine, Razvi Yousuf, Iyer Surabhi Bhaskar, Martinez-Naharro Ana, Bandera Francesco, Lim Sze Chi, Frost Matthew, Ezekowitz Justin, Lam Carolyn S P, Moody William, Whelan Carol, Lachmann Helen, Wechelakar Ashutosh, Emdin Michele, Hawkins Philip N, Solomon Scott David, Gillmore Julian D, Fontana Marianna

СтатьяПеревод пока не подготовлен

Аннотация

AIMS: In transthyretin amyloid cardiomyopathy (ATTR-CM), reduced stroke volume (SV) portends a poor prognosis. Artificial intelligence (AI) enables rapid, standardized assessment of left ventricular outflow tract velocity-time integral (LVOT-VTI), which is a reliable surrogate for SV. We investigated longitudinal changes in AI-derived LVOT-VTI as outcome predictors in ATTR-CM.

METHODS AND

RESULTS

Consecutive patients with ATTR-CM underwent baseline and 12 ± 1 month transthoracic echocardiography between 2007 and 2021. Scans were processed by an AI platform for fully automated measurements including LVOT-VTI. Changes in echocardiographic variables were related to all-cause mortality in a landmark analysis using multivariable Cox models adjusting for clinical covariates (age, sex, TTR genotype, atrial fibrillation status, New York Heart Association class and National Amyloidosis Centre stage). Time-dependent receiver-operating characteristic analysis identified the optimal threshold of LVOT-VTI change. A total of 752 patients (74 ± 9 years; 88% men; 66% wild-type) were followed for a median of 3.3 years (interquartile range 2.1-5.0 years), during which 334 (44.4%) died. Among changes in echocardiographic parameters over 12 months, only LVOT-VTI change remained independently prognostic (adjusted hazard ratio [HR] per 1% decrease 0.994, p = 0.025). A ≥5% decrease (n = 377 patients, 50%) independently predicted all-cause mortality (adjusted HR 1.41, 95% confidence interval 1.13-1.76; p = 0.003), and improved risk reclassification (integrated discrimination improvement = 0.012; continuous net reclassification improvement = 0.21, both p < 0.001).

CONCLUSIONS

A ≥5% decrease of AI-derived LVOT-VTI over 12 months, a simple indicator of SV loss, is independently associated with worse outcome in ATTR-CM. Routine monitoring of this automated AI metric may guide earlier therapeutic escalation and is a possible endpoint for future trials.

Для цитирования: Venneri Lucia, Aimo Alberto, Porcari Aldostefano, Sezer Irem, Ioannou Adam, Sheikh Awais, Mansell Josephine, Razvi Yousuf, Iyer Surabhi Bhaskar, Martinez-Naharro Ana, Bandera Francesco, Lim Sze Chi, Frost Matthew, Ezekowitz Justin, Lam Carolyn S P, Moody William, Whelan Carol, Lachmann Helen, Wechelakar Ashutosh, Emdin Michele, Hawkins Philip N, Solomon Scott David, Gillmore Julian D, Fontana Marianna. Artificial intelligence-based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis.. European journal of heart failure. 2025. DOI: 10.1002/ejhf.70073.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.